PAVmed (PAVM) Stock Overview
Engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
PAVM Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
PAVmed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.57 |
| 52 Week High | US$28.44 |
| 52 Week Low | US$6.00 |
| Beta | 0.97 |
| 1 Month Change | 30.56% |
| 3 Month Change | -9.45% |
| 1 Year Change | -50.81% |
| 3 Year Change | -96.26% |
| 5 Year Change | -99.14% |
| Change since IPO | -99.84% |
Recent News & Updates
Recent updates
Is PAVmed (NASDAQ:PAVM) Using Debt Sensibly?
Nov 18
Veris Health's NIH Grant May Boost Future Revenue, But Financing Uncertainty Could Persist
Strategic restructuring and subsidiary deconsolidation aim to strengthen the financial structure and improve net margins.Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?
Jan 29Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?
Aug 17PAVmed Non-GAAP EPS of -$0.17 beats by $0.03
Aug 16PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress
Jul 05Start Accumulating PAVmed
Dec 24We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth
Sep 02PAVmed: Long Term Investment Case Remains Despite Weak Q2
Aug 23PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans
May 19Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?
Dec 16Shareholder Returns
| PAVM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 10.6% | -2.0% | -1.4% |
| 1Y | -50.8% | -8.9% | 12.9% |
Return vs Industry: PAVM underperformed the US Medical Equipment industry which returned -7.7% over the past year.
Return vs Market: PAVM underperformed the US Market which returned 14.5% over the past year.
Price Volatility
| PAVM volatility | |
|---|---|
| PAVM Average Weekly Movement | 32.5% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PAVM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PAVM's weekly volatility has increased from 19% to 33% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 39 | Lishan Aklog | www.pavmed.com |
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform.
PAVmed Inc. Fundamentals Summary
| PAVM fundamental statistics | |
|---|---|
| Market cap | US$8.61m |
| Earnings (TTM) | -US$596.00k |
| Revenue (TTM) | US$29.00k |
Is PAVM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAVM income statement (TTM) | |
|---|---|
| Revenue | US$29.00k |
| Cost of Revenue | US$181.00k |
| Gross Profit | -US$152.00k |
| Other Expenses | US$444.00k |
| Earnings | -US$596.00k |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | -524.14% |
| Net Profit Margin | -2,055.17% |
| Debt/Equity Ratio | 26.8% |
How did PAVM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/03 12:45 |
| End of Day Share Price | 2026/02/03 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PAVmed Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Raymond Myers | Benchmark Company |
| Anthony Vendetti | Maxim Group |